Contents:

EXECUTIVE SUMMARY Scope Datamonitor insight into the cancer hormonals market Patent expiries of key agents will put intense pressure on cancer franchises over the next decade. To offset generic switching, significant differentiation amongst new products must be achieved. Current, late-stage pipeline products are unlikely to fulfill this requirement, hence, R&D investment should be increased and/or diversified. Pharmaceutical companies' preferred strategy of maximising the commercial lifecycle of hormonal products has been to reformulate, or gain approval for new indications. With few innovative products expected to be launched into the hormonals market in the short to medium term, Datamonitor believes that such strategies will become ever more important in bridging a revenue gap sprung from insufficient innovation. AstraZeneca's hormonal therapy, Arimidex (anastrozole) may provide a valuable alternative to tamoxifen. However, this will depend considerably on the company's ability to change physicians' attitude towards the use of aromatase inhibitors as first-line breast cancer and differentiation through reformulation. Key metrics TABLE OF CONTENTS MARKET DEFINITION Market definition Therapy classes covered Disease indications Class definitions LHRH agonists Anti-androgens Anti-estrogens Aromatase inhibitors Progestagens Historical development of hormonal agents Hormonal class comparisons Prostate cancer Breast cancer Key developments in hormonal drug class New product launches/reformulation New indications Key patent expiries/generic competitions Price cuts in Japan Lupron court case GLOBAL MARKET ANALYSIS Hormonal market analysis by drug class Overview of global hormonal market Key trends in the global hormonal market Class growth analysis LHRH agonists Overview of the global LHRH agonist market Key trends in the global LHRH agonist market Lupron/Leuplin Zoladex Anti-androgens Overview of the global anti-androgen market Key trends in the global anti-androgen market Casodex Eulexin/Odyne Androcur Anti-estrogens Overview of the global anti-estrogen market Key trends in the global anti-estrogen market Nolvadex Fareston Aromatase inhibitors Overview of the global aromatase inhibitor market Key trends in the global aromatase inhibitor market Arimidex Femara Lentaron Aromasin Progestagens Overview of the global progestagens market Key trends in the global progestagen market Depo-Provera Megace 2000 COUNTRY MARKET ANALYSIS The significance of major countries in the global hormonal market Overview of the global hormonal market Country positioning in the hormonals market Breakdown of the country markets by class The US hormonals market analysis Environmental drivers of the US market Japan hormonals market analysis Environmental drivers in Japan France hormonals market analysis Environmental drivers in France Germany hormonals market analysis Environmental drivers in Germany Italy hormonals market Environmental drivers in Italy Spain hormonals market analysis Environmental drivers in Spain UK hormonals market Environmental drivers in the UK LIFECYCLE MANAGEMENT Global drug class lifecycle in hormonals Reformulations of cancer hormonal agents New indications for cancer hormonal agents Lifecycle management case studies Lupron: reaching the maximum commercial potential Casodex: new indications to counter generic erosion Nolvadex: life extension through commercial agreement with Barr MARKET FORECASTS Forecasting methodology Trends in the hormonals market to 2008 Forecast overview Class forecast SUPPORTING DATA Treatment of breast and prostate cancer Trends in the epidemiology of breast and prostate cancer Incidence of breast and prostate cancer Prevalence of breast and prostate cancer Classification of breast and prostate cancer Breast cancer Prostate cancer APPENDIX List of tables List of figures LIST OF FIGURES Sales data research methodology Introduction Hypothesis formulation Hypothesis testing Data verification with key contacts Quality control Quantification of data reliability Confidence ratings Exchange rates DATAMONITOR HEALTHCARE CONTACT DETAILS